Abstract:Objective: The aim of this study was to describe clinical features in different subtypes of chronic pulmonary aspergillosis (CPA)-simple aspergilloma (SA), chronic cavitary pulmonary aspergillosis (CCPA), chronic fibrosing pulmonary aspergillosis (CFPA), aspergillus nodule (AN), and subacute invasive aspergillosis (SAIA), respectively, and identify long-term prognosis of CPA. Methods: We reviewed patients diagnosed with different subtypes of CPA from 2002 to 2020 at Nanjing Jinling Hospital, China. We analyzed the clinical and survival information of five different subgroups. A Cox regression model was used to explore proper antifungal duration and long-term survival factors of CCPA and SAIA. Results: A total of 147 patients with CPA were included, consisting of 11 SA, 48 CCPA, 5 CFPA, 12 AN, and 71 SAIA. The most common underlying pulmonary disease was pulmonary tuberculosis (n = 49, 33%), followed by bronchiectasis (n = 46, 31.3%) and chronic obstructive pulmonary disease (COPD) or emphysema (n = 45, 30.6%), while in SAIA and CFPA groups, the most common was COPD or emphysema (45.1 and 100%). Cough (85%), expectoration (70.7%), hemoptysis (54.4%), and fever (29.9%) were common symptoms, especially in CCPA, CFPA, and SAIA groups. The common imaging manifestations included cavitation (n = 94, 63.9%), fungal ball (n = 54, 36.7%), pleural thickening (n = 47, 32.0%), and bronchiectasis (n = 46, 31.3%). SAIA and CFPA groups had a lower value of hemoglobin (HB) and serum albumin (ALB) with higher C-reactive protein and erythrocyte sedimentation rate. The positive rate of sputum culture, serum galactomannan (GM), and bronchoalveolar lavage fluid GM was 32.7% (36/110), 18.4% (18/98), and 48.7% (19/39), respectively. There were 64.6% (31/48) patients with CCPA and 25.4% (18/71) patients with SAIA who received surgery and the 5-year cumulative survival rate was 92.1 and 66.6%, respectively. SAIA, old age, male, low body mass index (BMI), COPD or emphysema, multiple distribution, low serum ALB, and positive sputum culture were adverse prognosis factors for SAIA and CCPA group, and BMI ≤ 20.0 kg/m2 was independently associated with increased mortality (hazard ratio (HR) 5.311, 95% CI 1.405-20.068, p = 0.014). Multivariable Cox regression indicated that surgery (HR 0.093, 95% CI 0.011-0.814, p = 0.032) and antifungal duration >6 months (HR 0.204, 95% CI 0.060-0.696 p = 0.011) were related to improved survival. Conclusion: The clinical features and laboratory test performance are different among SA, CCPA, CFPA, AN, and SAIA. Low BMI was an independent risk factor for survival. Selective surgery and antifungal duration over 6 months were associated with improved survival.

Role of serial fluorodeoxyglucose positron emission tomography-computed tomography (18FDG-PET-CT) in assessing treatment response in treatment naïve chronic pulmonary aspergillosis subjects

Role of C-Reactive Protein and Erythrocyte Sedimentation Rate in the Diagnosis and Monitoring of Treatment Response in Treatment Naïve Subjects with Chronic Pulmonary Aspergillosis

Utility of CT Assessment in Hematology Patients with Invasive Aspergillosis: a Post-Hoc Analysis of Phase 3 Data

Utility Of Computed Tomography For The Diagnosis Of Invasive Aspergillosis In Hematological Malignancy

Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement

Chronic pulmonary aspergillosis incidence in newly detected pulmonary tuberculosis cases during follow‐up

Prospective study of the serum Aspergillus-specific IgG, IgA and IgM assays for chronic pulmonary aspergillosis diagnosis

Clinical Significance of Aspergillus Sensitisation in Chronic Pulmonary Aspergillosis

Innate and adaptive immune responses in subjects with CPA secondary to post‐pulmonary tuberculosis lung abnormalities

Incidence and prevalence of chronic pulmonary aspergillosis in patients with post‐tuberculosis lung abnormality: Results from a community survey in North India

[Serum Antigens Assay Combined with Chest CT Scan in Diagnosis of Invasive Pulmonary Aspergillosis].

The Utility of Real-time PCR, Metagenomic Next-generation Sequencing, and Culture in Bronchoalveolar Lavage Fluid for Diagnosis of Pulmonary Aspergillosis

[Chronic Necrotizing Pulmonary Aspergillosis: Diagnosis and Treatment].

18F-FDG positron emission tomography as a marker of disease activity and treatment response in ankylosing spondylitis and psoriatic arthritis

Chronic pulmonary aspergillosis in Taiwan: Disease burden, diagnosis, treatment, and outcomes

Evaluation of a Commercial Quantitative Aspergillus Fumigatus-Specific IgM Assay for the Diagnosis of Invasive Pulmonary Aspergillosis.

Exhaled Volatile Organic Compounds for Identifying Patients With Chronic Pulmonary Aspergillosis

[18F]FDG PET and CT findings at therapy completion of pulmonary tuberculosis: comparison between HIV-positive and HIV-negative patients and impact on treatment response assessment

Loss to Follow-Up Associated Factors in Patients with Chronic Pulmonary Aspergillosis and Its Impact on the Disease Prognosis

Aspergillus fumigatus: Is Dual-Tracer 18 FDG/ 68 Ga-FAPI PET/CT Capable of Distinguishing Fungal Infection and Unspecific Inflammation From Recurrent Lung Cancer?

Clinical Features, Diagnostic Test Performance, and Prognosis in Different Subtypes of Chronic Pulmonary Aspergillosis